Clinical Academic Group (CAG)
Clinical Academic Groups (CAGs) bring together Clinical and Academic groupings to offer care and treatment, based upon reliable research evidence that it works.
Addictions First is the newsletter of the Addictions CAG. Copies can be downloaded by clicking on the links found to the left of this page.
A link to the SLaM CAG website is found here.
The Addictions CAG is made up of Inpatient and community addiction services, research activity and education from within the Institute of Psychiatry, Psychology & Neuroscience’s newly established Addictions Department, as well as within our Biomedical Research Centre ‘Substance use disorders’.
Click here to see Professor Sir John Strang talking about the CAG structure.
Examples of our achievements
- The National Treatment Agency’s standard measurement for assessing the effectiveness of treatments – the Treatment Outcomes Profile (TOP) – was developed by researchers and clinicians from the NAC.
- Research undertaken here over the last 30 years has informed smoking cessation policy and practice internationally and is now measured, across the UK, by the ‘Russell Standard’ in recognition of its Maudsley/Institute of Psychiatry, Psychology & Neuroscience origins.
- We are currently coordinating demonstration projects of alcohol screening and intervention across primary care, Accident and Emergency and the criminal justice system though a major Alcohol Screening and Brief Intervention Research Programme.
- The piloting of supervised injecting clinics, delivering intensive treatments for long-term chronic heroin addiction, has shown real improvements in terms of reduced crime and illicit drug use. The full results of the RIOTT trial will be published later this year.
Looking to the future
- The emphasis of our research is on ‘what works’ in the prevention and treatment of substance misuse. Our network of clinicians, researchers and clinical teachers have a shared commitment to excellence in prevention and treatment work, and to supporting and strengthening national and international endeavours in this field.
- Seventy percent of people in treatment for alcohol dependence relapse. Our researchers are looking at better ways to provide treatment with a study into developing assertive community treatment for alcohol dependence.
- We are conducting a major study, the first of its kind in the world, to explore whether the number of drug overdose deaths among recently released prisoners can be reduced by providing family members with Naloxone (a heroin antidote injection).
- We are launching a five-year research programme to evaluate the use of voucher schemes in improving treatment retention rates for people with drug problems. We are working closely with the Centre for the Study of Incentives in Health at Guy’s Hospital.
- As new drugs come on stream, new treatments are developed. The rise of ‘legal highs’ and alternatives to proscribed substances presents fresh challenges. We are currently developing services to address the growing use of GBL, a cleaning fluid which on ingestion becomes the dance drug GHB.
- Preventure is a prevention programme targeting vulnerable young people aged 13 -16, at risk of developing substance misuse and emotional/behavioural problems. The programme targets known risk factors for early onset substance misuse.
- The IMAGEN project is looking at genetic factors in perception and behaviour that manifest in adolescence and carry the risk for psychopathology later in life. This is the first pan-European multicentre functional and structural genetic-neuroimaging study of a cohort of over 2,000 14-year-olds.